Physician networking platform Doximity beats Q2 revenue estimates

Doximity

06/11/2025 21:26

Overview

Doximity fiscal Q2 revenue grows 23% yr/yr, beating analysts' expectations

Adjusted EBITDA for fiscal Q2 beats consensus, rising 32% yr/yr

Company highlights growth in AI tools and user engagement

Outlook

Doximity sees Q3 revenue between $180 mln and $181 mln

Company expects Q3 adjusted EBITDA between $103 mln and $104 mln

Doximity projects FY2026 revenue between $640 mln and $646 mln

Company anticipates FY2026 adjusted EBITDA between $351 mln and $357 mln

Result Drivers

AI TOOL ADOPTION - Co attributes revenue growth to increased use of AI tools, with AI Scribe and DoxGPT users growing over 50% from prior qtr

USER ENGAGEMENT - Record 650,000 prescribers used workflow tools, contributing to revenue growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$168.53 mln
$157.61 mln (18 Analysts)
Q2 Net Income
$62.06 mln
Q2 Adjusted EBITDA
Beat
$100.83 mln
$87.54 mln (18 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 7 "hold" and 2 "sell" or "strong sell"

The average consensus recommendation for the software peer group is "buy"

Wall Street's median 12-month price target for Doximity Inc is $72.50, about 11.7% above its November 5 closing price of $63.99

The stock recently traded at 40 times the next 12-month earnings vs. a P/E of 39 three months ago

Press Release: ID:nBw2HT3Dqa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)